Phaseline

Companies › Arbor Biotechnologies

Arbor Biotechnologies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABO-101
Gene therapy delivering a functional copy of the AGXT gene to hepatocytes
AGXTPhase 1Primary Hyperoxaluria Type 1 (PH1)Mar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06839235ABO-101Phase 1Primary Hyperoxaluria Type 1 (PH1)Metabolic and endocrineMar 2029

Targets

AGXT (1)

Companies with the same targets

YolTech Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.